Summary Safety Review - PRADAXA (dabigatran etexilate) - Assessing the potential risk of liver injury

May 7, 2018

Product

Pradaxa (dabigatran etexilate)

Potential Safety Issue

Liver injury

Key Messages

Overview

Health Canada reviewed the potential risk of liver injury with Pradaxa after receiving reports of severe liver injury from the manufacturer. The manufacturer was asked to provide all available data on Pradaxa and the risk of liver injury.

Use in Canada

Safety Review Findings

Conclusions and Actions

Additional Information

The Pharmaceutical and Medical Devices Agency of Japan issued a risk communicationFootnote 1 and updated the product label on September 12, 2017 to include liver injury (i.e. 'acute hepatic failure, hepatic function disorder, and jaundice').

The analysis that contributed to this safety review included scientific and medical literature, Canadian and international information, and what is known about the use of this drug both in Canada and internationally.

For additional information, contact the Marketed Health Products Directorate.

Reference

Footnote 1

Summary of investigation results Dabigatran etexilate methanesulfonate.

Return to footnote 1 referrer

Footnote

Footnote a

Canadian reports can be accessed through the Canada Vigilance Online Database.

Return to footnote a referrer

Page details

2018-05-07